IBEX Targets Osteoporosis with £2m Funding Injection
Deal News | Apr 22, 2025 | Business Cloud
IBEX Innovations, a bone health specialist based in Durham, has successfully secured a £2 million funding round to further its mission of improving osteoporosis diagnostics. The company is focused on converting standard X-rays into tools for identifying osteoporosis, a condition often only detected after fractures have occurred. With existing partnerships with original equipment manufacturers in the X-ray and mammography sectors, IBEX aims to deploy its 'IBEX BH' product in clinical settings this year, enhancing case finding, which could lead to cost savings for systems like the NHS. Chief Clinical Advisor, Dr. Sarah Jarvis MBE, highlights the importance of diagnosing what she terms a 'silent disease' before fractures occur. CEO Paul Scott extends gratitude to investors and healthcare professionals who support the vision of better outcomes for millions at risk. This funding round reinforces IBEX's commitment to innovation in the MedTech space.
Sectors
- MedTech
- Healthcare
Geography
- United Kingdom – IBEX Innovations is based in Durham, UK, and the NHS—a major healthcare network within the UK—is mentioned in the article as a potential beneficiary of the company's advancements.
Industry
- MedTech – The article discusses advancements in medical technology, specifically leveraging X-ray imaging to diagnose osteoporosis, an initiative spearheaded by IBEX Innovations.
- Healthcare – IBEX Innovations' focus on osteoporosis diagnostics and its potential cost savings for the NHS places the company within the broader healthcare sector.
Financials
- £2 million – The amount raised by IBEX Innovations in the latest funding round to advance its osteoporosis diagnostic technology.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| IBEX Innovations | Target Company | Company | A MedTech company focused on improving diagnostics for osteoporosis through innovative use of X-ray technology. |
| Dr. Sarah Jarvis MBE | Chief Clinical Advisor | Person | Provides clinical guidance at IBEX Innovations and emphasizes the need for earlier diagnosis of osteoporosis. |
| Paul Scott | CEO | Person | Chief Executive Officer of IBEX Innovations, expressing gratitude towards the investors and partners in the technology’s development. |
| NHS | Beneficiary | Government | The National Health Service in the UK, which could benefit from cost savings through improved osteoporosis diagnostics from IBEX. |